Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism

@article{Megyeri2007EffectsO2,
  title={Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism},
  author={K. Megyeri and B. Mark{\'o} and N. Sziray and I. Gacs{\'a}lyi and L. H{\'a}rsing},
  journal={Brain Research Bulletin},
  year={2007},
  volume={71},
  pages={501-507}
}
Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA receptor antagonists can be used as adjuvant therapy to improve the effects of levodopa. Systemic administration of levodopa, the precursor of dopamine, increases brain dopamine turnover rate and this elevated turnover is believed to be essential for successful treatment of Parkinson's disease. However, long-term treatment of patients with levodopa often leads to… Expand
9 Citations
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
  • 46
  • PDF
Striatal Astrocytes Act as a Reservoir for L-DOPA
  • 35
  • PDF
The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.
  • I. Mellor
  • Biology, Medicine
  • Future medicinal chemistry
  • 2010
  • 26

References

SHOWING 1-10 OF 58 REFERENCES
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease
  • 130
  • PDF
Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats
  • 33
Dopamine receptor interactions: some implications for the treatment of Parkinson's disease
  • 155
...
1
2
3
4
5
...